# US 2013/0295082 A1 · Antibody formulations and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295082 A1
- Document ID: US20130295082A1
- Status: Published application
- Kind: A1
- Application number: 13/660,957
- Filed: 2012-10-25
- Published: 2013-11-07
- Earliest claimed: 2011-10-25
- Assignees: Onclave Therapeutics
- Inventors: PATRICK GARIDEL; Isaac Craig Henderson; Pamela Klein
- Web page: https://patentgrep.com/patent/US20130295082A1

## CPC

- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/195: having an amino group
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/69: Boron compounds
- A61K 38/07: Tetrapeptides
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 11/08: Bronchodilators
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/08: for leprosy
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/18: against material from animals or humans
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.

## Claims

### Claim 1

A pharmaceutical formulation comprising:
(a) a chimeric or humanized version of antibody 2A4 (ATCC Accession Number PTA-9662) or of antibody 7D8 (ATCC Accession Number PTA-9468), or fragment thereof, that specifically competes for binding to antigen with 2A4 or 7D8, wherein the antibody is present at a concentration within the range from about 1 mg/mL to about 100 mg/mL;
(b) histidine buffer present at a concentration within the range from about 20 mM to about 30 mM;
(c) trehalose present at a concentration within the range from about 210 mM to about 250 mM; and
(d) polysorbate 20 present at a concentration within the range from about 0.005% to about 0.05% by weight;
wherein the formulation is characterized by a pH within the range from about 6 to about 7.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the antibody is a humanized version of antibody 2A4.

### Claim 3 (depends on 1)

The formulation of claim 1, wherein the antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 4.

### Claim 4 (depends on 1)

The formulation of claim 1, wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 5.

### Claim 5 (depends on 3)

The formulation of claim 3, wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 5.

### Claim 6 (depends on 5)

The formulation of claim 5, wherein the antibody comprises a light chain comprising an amino acid sequence set forth as SEQ ID NO: 13 and a heavy chain comprising an amino acid sequence set forth as any one of SEQ ID NO: 14-16.

### Claim 7 (depends on 6)

The formulation of claim 6, wherein the antibody comprises a light chain comprising an amino acid sequence set forth as SEQ ID NO: 13 and a heavy chain comprising an amino acid sequence set forth as SEQ ID NO: 15.

### Claim 8 (depends on 1)

The formulation of claim 1, wherein the antibody comprises a light chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs: 6, 7, and 8, and a heavy chain variable region comprising three complementarity regions set forth as SEQ ID NOs: 9, 10, and 11.

### Claim 9 (depends on 1)

The formulation of claim 1, wherein the antibody is a humanized or chimeric version of antibody 7D8 produced by ATCC Accession Number PTA-9468.

### Claim 10 (depends on 1)

The formulation of claim 1, wherein the antibody comprises a light chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs: 12, 7, and 8, and a heavy chain variable region comprising three complementarity regions set forth as SEQ ID NOs: 9, 10, and 11.

### Claim 11 (depends on 1)

The formulation of any one of claims 1, wherein the antibody is present at a concentration within the range from about 5 mg/mL to about 15 mg/mL.

### Claim 12 (depends on 11)

The formulation of claim 11, wherein the antibody is present at a concentration of about 10 mg/mL.

### Claim 13 (depends on 1)

The formulation of any one of claims 1, wherein the antibody is present at a concentration within the range from about 25-75 mg/mL.

### Claim 14 (depends on 13)

The formulation of claim 13, wherein the antibody is present at a concentration of about 50 mg/mL.

### Claim 15 (depends on 1)

The formulation of any one of claims 1, wherein the histidine buffer is present at a concentration of about 25 mM.

### Claim 16 (depends on 15)

The formulation of claim 15, wherein the histidine buffer comprises L-histidine and L-histidine HCl monohydrate.

### Claim 17 (depends on 16)

The formulation of claim 16, wherein the L-histidine is present at a concentration within the range from about 16 mM to about 22 mM and the L-histidine HCl monohydrate is present at a concentration within the range from about 4 mM to about 8 mM.

### Claim 18 (depends on 1)

The formulation of any one of claims 1, wherein the trehalose is present at a concentration of about 230 mM.

### Claim 19 (depends on 1)

The formulation of any one of claims 1, which is characterized by an osmolality of about 300 mOsm/kg.

### Claim 20 (depends on 1)

The formulation of any one of claims 1, wherein less than about 10% of the antibody is present as an aggregate in the formulation.

### Claim 21 (depends on 1)

The formulation of any one of claims 1, which further comprises a bulking agent.

### Claim 22 (depends on 1)

The formulation of any one of claims 1, which is sterile.

### Claim 23 (depends on 1)

The formulation of any one of claims 1, which is stable upon freezing and thawing.

### Claim 24

A pharmaceutical formulation comprising:
(a) an antibody comprising a light chain comprising an amino acid sequence set forth as SEQ ID NO: 13 and a heavy chain comprising an amino acid sequence set forth as any one of SEQ ID NOs: 14-16, and which is present at a concentration of about 10 mg/mL;
(b) a histidine buffer present at a concentration of about 25 mM;
(c) trehalose present at a concentration of about 230 mM;
(d) polysorbate 20 present at a concentration of about 0.2 g/L; and
(e) a pH of about 6.5.

### Claim 25 (depends on 24)

The formulation of claim 24, wherein the antibody comprises a light chain comprising an amino acid sequence set forth as SEQ ID NO: 13 and a heavy chain comprising an amino acid sequence set forth as SEQ ID NO: 15.

### Claim 26

A pharmaceutical formulation comprising:
(a) an antibody, which is antibody 2A4 (ATCC Accession Number PTA-9662), antibody 7D8 (ATCC Accession Number PTA-9468), or a chimeric or humanized version of antibody 2A4 or of antibody 7D8, or fragment thereof, that specifically competes for binding to antigen with 2A4 or 7D8, wherein the antibody is present at a concentration within the range from about 50 mg/mL to about 100 mg/mL;
(b) a buffer;
(c) a non-reducing sugar; and
(d) a non-ionic surfactant.

### Claim 27

A lyophilized formulation of an antibody, comprising
(a) a humanized version of antibody 2A4 (ATCC Accession Number PTA-9662) or antibody 7D8 (ATCC Accession Number PTA-9468) or antigen binding fragment thereof;
(b) histidine;
(c) trehalose; and
(d) polysorbate 20.

### Claim 28 (depends on 27)

The lyophilized formulation of claim 27, wherein the formulation has a pH of between about 6 to about 7 when reconstituted.

### Claim 29 (depends on 28)

The lyophilized formulation of claim 28, wherein the formulation has a pH of about 6.5 when reconstituted.

### Claim 30 (depends on 27)

The lyophilized formulation of claim 27, comprising about 100 mg to about 1000 mg of the antibody.

### Claim 31 (depends on 27)

The lyophilized formulation of claim 27, wherein the polysorbate 20 is present at a concentration within the range from about 0.005% to about 0.05% by weight.

### Claim 32 (depends on 27)

The lyophilized formulation of claim 27, that enables reconstitution to yield an aqueous solution comprising:
(a) an antibody comprising a light chain comprising an amino acid sequence set forth as SEQ ID NO: 13 and a heavy chain comprising an amino acid sequence set forth as any one of SEQ ID NOs: 14-16, and which is present at a concentration of about 10 mg/mL;
(b) a histidine buffer present at a concentration of about 25 mM;
(c) trehalose present at a concentration of about 230 mM;
(d) polysorbate 20 present at a concentration of about 0.2 g/L; and
(e) a pH of about 6.5.

### Claim 33 (depends on 32)

The lyophilized formulation of claim 32, wherein the lyophilized formulation comprises about 100 mg of the antibody and enables reconstitution with sterile water.

### Claim at position 34

34-36. (canceled)

### Claim 37

A nucleic acid comprising a nucleotide sequence encoding any one of SEQ ID NOs: 13, 14-16, 19, 20, 22 or 23.

### Claim at position 36

38-40. (canceled)

### Claim 41 (depends on 37)

A vector comprising at least one nucleic acid of claim 37.

### Claim at position 38

42-44. (canceled)

### Claim 45 (depends on 37)

A host cell having stably incorporated into its genome at least one nucleic acid of claim 37.

### Claim 46 (depends on 45)

The host cell of claim 45, wherein the host cell is a CHO cell.

### Claim 47

(canceled)

### Claim 48 (depends on 38)

The host cell of claim 38 having stably incorporated into its genome a nucleic acid comprising the nucleotide sequence encoding SEQ ID NO: 19 and a nucleic acid comprising the nucleotide sequence encoding SEQ ID NO: 22.

### Claim 49 (depends on 38)

The host cell of claim 38 having stably incorporated into its genome a nucleic acid comprising the nucleotide sequence encoding SEQ ID NO: 20 and a nucleic acid comprising the nucleotide sequence encoding SEQ ID NO: 23.

### Claim 50

(canceled)

### Claim 51 (depends on 1)

A method of making a pharmaceutical formulation comprising:
(a) culturing mammalian cells having stably incorporated into their genome one or more nucleic acids encoding the light and heavy chains of a humanized 2A4 antibody so that the cells secrete the antibody into the cell culture media, and purifying the antibody from the cell culture media;
(b) and preparing the formulation of claim 1.

### Claim 52

(canceled)

### Claim 53 (depends on 52)

The method of claim 52, wherein the nucleic acid encoding the light chain of a humanized 2A4 antibody comprises a nucleotide sequence encoding SEQ ID NO: 13, and wherein the nucleic acid encoding the heavy chain of a humanized 2A4 antibody comprises a nucleotide sequence encoding SEQ ID NO: 15.

### Claim 54 (depends on 53)

The method of claim 53, wherein the nucleic acid encoding the light chain of a humanized 2A4 antibody comprises the nucleotide sequence of SEQ ID NO: 19, and wherein the nucleic acid encoding the heavy chain of a humanized 2A4 antibody comprises the nucleotide sequence of SEQ ID NO: 22.

### Claim 55 (depends on 54)

The method of claim 54, wherein the nucleic acid encoding the light chain of a humanized 2A4 antibody comprises the nucleotide sequence of SEQ ID NO: 20, and wherein the nucleic acid encoding the heavy chain of a humanized 2A4 antibody comprises the nucleotide sequence of SEQ ID NO: 23.

### Claim at position 50

56-57. (canceled)

### Claim 58 (depends on 1)

A method of therapeutically or prophylactically treating a human patient having or at risk for having amyloidosis characterized by the presence of amyloid protein fibrils, the method comprising administering to the patient an effective dosage of the formulation of claim 1.

### Claim 59 (depends on 58)

The method of claim 58, wherein the human patient has amyloid A amyloidosis characterized by the presence of amyloid A protein fibrils.

### Claim 60 (depends on 25, 59)

The method of claim 59, wherein the formulation is the formulation of claim 25.

### Claim 61 (depends on 60)

The method of claim 60, wherein the human patient has AL amyloidosis characterized by the presence of amyloid light chain-type protein fibrils.

### Claim 62

(canceled)

### Claim 63 (depends on 61)

The method of claim 61, wherein the patient is also treated with one or both of melphalan, bortezomib, lenolidomide or carfilzomib.

### Claim 64 (depends on 63)

The method of claim 63, wherein the patient is treated with melphalan and/or bortezomib prior to treatment with the formulation.

### Claim 65 (depends on 64)

The method of claim 64, wherein the patient is treated with melphalan and/or bortezomib concurrently with treatment with the formulation.

### Claim 66 (depends on 64)

The method of claim 64, wherein the patient is treated with melphalan and/or bortezomib subsequent to treatment with the formulation.

### Claim 67 (depends on 61)

The method of claim 61, wherein the AL amyloidosis is associated with a dyscrasia of the B lymphocyte lineage.

### Claim 68 (depends on 67)

The method of claim 67, wherein the dyscrasia is a malignancy.

### Claim 69 (depends on 68)

The method of claim 68, wherein the malignancy is multiple myeloma.

### Claim 70 (depends on 61)

The method of claim 61, wherein the formulation is administered in multiple dosages.

### Claim 71 (depends on 70)

The method of claim 70, wherein the formulation is administered at a frequency in a range of about daily to about annually.

### Claim 72 (depends on 71)

The method of claim 71, wherein the frequency is in a range of about every other week to about every three months.

### Claim 73 (depends on 61)

The method of claim 61, wherein the formulation is administered intravenously at a dose in a range from about 10 mg to about 5000 mg humanized 2A4 drug substance.

### Claim 74 (depends on 73)

The method of claim 73, wherein the formulation is administered at a dose in a range from about 30 mg to about 2500 mg humanized 2A4 drug substance at a frequency in a range of about every other week to about every other month.

### Claim 75 (depends on 73)

The method of claim 73, wherein the formulation is administered once a month.

### Claim 76 (depends on 73)

The method of claim 73, wherein the dose is about 30 mg humanized 2A4 drug substance.

### Claim 77 (depends on 73)

The method of claim 73, wherein the dose is about 100 mg humanized 2A4 drug substance.

### Claim 78 (depends on 73)

The method of claim 73, wherein the dose is about 300 mg humanized 2A4 drug substance.

### Claim 79 (depends on 73)

The method of claim 73, wherein the dose is about 1000 mg humanized 2A4 drug substance.

### Claim 80 (depends on 73)

The method of claim 73, wherein the dose is about 2500 mg humanized 2A4 drug substance.

### Claim 81

A method of therapeutically or prophylactically treating a human patient having or at risk for having light chain (AL) amyloidosis characterized by the presence of amyloid fibrils, deposits or prefibrillar aggregates, comprising administering to the patient an effective dosage of a pharmaceutical formulation comprising:
(a) an antibody comprising a light chain comprising an amino acid sequence set forth as SEQ ID NO: 13 and a heavy chain comprising an amino acid sequence set forth as any one of SEQ ID NOs: 14-16, and which is present at a concentration of about 10 mg/mL;
(b) a histidine buffer present at a concentration of about 25 mM;
(c) trehalose present at a concentration of about 230 mM;
(d) polysorbate 20 present at a concentration of about 0.2 g/L; and
(e) a pH of about 6.5.

### Claim 82 (depends on 81)

The method of claim 81, wherein the dosage is from about 0.5 mg/kg to about 30 mg/kg of the antibody administered intravenously or subcutaneously at a frequency of from about weekly to about quarterly.

### Claim 83 (depends on 82)

The method of claim 82, wherein the frequency of administration is once every 28 days.

### Claim 84 (depends on 82)

The method of claim 82, wherein the dosage is about 0.5 mg/kg to about 8 mg/kg.

### Claim 85 (depends on 82)

The method of claim 82, wherein the dosage is about 8 mg/kg to about 30 mg/kg.

### Claim 86

A pharmaceutical product, comprising:
(a) a vial comprising about 100 mg antibody in powder form;
(b) instructions for reconstitution of the antibody; and
(c) instructions for preparing the reconstituted antibody for infusion, wherein:
(i) the antibody comprises a light chain comprising an amino acid sequence set forth as SEQ ID NO: 13 and a heavy chain comprising an amino acid sequence set forth as any one of SEQ ID NOs: 14-16; and
(ii) the reconstitution instructions require reconstitution with water for injection to an extractable volume of 10 mL.
